drugset / Trial / NCT01498874

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

NCT01498874

Phase 2 Completed 127 enrolled XOMA (US) LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether gevokizumab is effective in the treatment of moderate to severe acne vulgaris.

Timeline

Start
2011-12
Primary completion
2013-04
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject gevokizumab Monoclonal antibody Subcutaneous

Indications